In celebration of National APP Week 2026, Lauren Miller, PA-C, reflected on nearly 20 years of practicing dermatology in Alabama and the opportunities the physician assistant ( PA) profession has ...

From new therapeutic data and late-breaking trials to evolving approaches to precision medicine, inflammatory disease, alopecia, and cutaneous oncology, EADV 2026 is positioned to provide a broad look ...

Ultrasound provides standardized HS assessment with consensus-based criteria, enabling detection of subclinical tunnels, inflammatory activity, and anatomic extent to optimize surgical planning and ...

Lauren Miller, PA-C, reflects on nearly 20 years in dermatology and how the PA profession has allowed her to grow as a clinician, educator, author, and mentor.

Two randomized, double-blind phase 3 trials showed LS mean UAS7 reductions of ~−20 at week 12 with both regimens versus ~−11 with placebo (P<.00001). Complete response (UAS7=0) at week 12 was ~42%–46% ...

Hidden operational costs, including clinician time and staffing inefficiencies, can erode profitability despite stable headline overhead. Training and onboarding demands should be modeled as recurring ...

A personal encounter with a dermatology PA reframed career possibilities, prompting retraining through EMT work, prerequisites, and dermatology assisting to enter PA practice. Patient impact is ...

FDA Fast Track for QRX003 in PSS enables enhanced agency interaction and potential rolling review, with possible pathways to Priority Review or Accelerated Approval if qualifying criteria are met.

Hidradenitis suppurativa often goes undiagnosed for years while patients quietly absorb pain, odor, and isolation. The panel examines why recognizing these signals early changes everything that ...

On this episode of Don't Be Rash, Lisa Swanson, MD, joined host Andrew C. Krakowski, MD, to walk through the pediatric psoriasis treatment ladder, from first-line topicals to biologics and a new oral ...

Certified PAs reporting dermatology practice rose to 4580 in 2021 from 2323 in 2013, reflecting rapid workforce growth that may mitigate specialty capacity constraints. Training and integrating NPs ...

Joshua Zeichner, MD, presents phase 3 results showing topical clascoterone 5% stays well tolerated for 12 months and boosts hair density, signaling a new DHT-blocking option. Twelve-month phase 3 data ...